Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPLATINUM: Nibrozetone + Chemotherapy in 3rd Line+ Small Cell Lung Cancer
NCT03699956Phase 3Terminated
- Sponsor
- EpicentRx
- Start
- Dec 2018
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Nibrozetone in small cell lung cancer (SCLC), sponsored by EpicentRx. Started Dec 2018; status: terminated.
02
Drugs
Nibrozetone
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03699956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03699956.